BiomedReports: Allos Therapeutics - A Small-Cap Cancer Biotech with an FDA Catalyst today is unveiling coverage on Allos Therapeutics, a promising small-cap cancer biotech with the potential for an upcoming FDA approval decision.

Los Angeles, CA, April 29, 2009 --(, a full news portal offering unbiased bio stock reporting and analysis about emerging biotech companies, today is unveiling coverage on Allos Therapeutics, a promising small-cap cancer biotech with the potential for an upcoming FDA approval decision.

Allos filed a new drug application late last month for pralatrexate (PDX) in the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). ALTH requested priority (six-month) review for the application, with an expected 60-day period for the FDA to accept the filing and rule on priority review status.

The priority review PDUFA date would be in late September of this year (versus 1/25/10 for standard, 10-month review).

PTCL comprises a biologically diverse group of blood-based cancers that typically have a worse prognosis than other types of lymphoma and are less responsive to traditional chemotherapy regimens. There are currently no agents approved by the FDA for the treatment of patients with PTCL.

ALTH is a promising small-cap cancer biotech with the potential for approval of PDX by the end of September if the FDA grants a priority review for the recently submitted NDA in the treatment of PTCL. The Company has zero debt, about 89M shares of stock outstanding after the recent public offering, and should end the year with around $80M in cash.

A complete report on the company and it's status with the FDA is available now at BiomedReports.Com:

About BiomedReports.Com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to BiomedReports.Com ( )

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

Mike Havrilla